287 related articles for article (PubMed ID: 35181160)
1. [Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials].
Lescoat A; Jouneau S; Uzunhan Y; Jégo P; Cottin V; Hachulla E
Rev Med Interne; 2022 Jun; 43(6):365-374. PubMed ID: 35181160
[TBL] [Abstract][Full Text] [Related]
2. Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
Richter P; Cardoneanu A; Dima N; Bratoiu I; Rezus C; Burlui AM; Costin D; Macovei LA; Rezus E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298342
[TBL] [Abstract][Full Text] [Related]
3. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
4. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP
Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399
[TBL] [Abstract][Full Text] [Related]
5. [Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis].
Hua-Huy T; Rivière S; Tiev KP; Dinh-Xuan AT
Rev Pneumol Clin; 2014 Dec; 70(6):335-42. PubMed ID: 25457218
[TBL] [Abstract][Full Text] [Related]
6. [How do I treat interstitial lung disease in systemic sclerosis?].
Riemekasten G
Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
[TBL] [Abstract][Full Text] [Related]
7. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D
Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946
[TBL] [Abstract][Full Text] [Related]
10. Interstitial Lung Disease Associated with Systemic Sclerosis.
Mismetti V; Si-Mohamed S; Cottin V
Semin Respir Crit Care Med; 2024 Jun; 45(3):342-364. PubMed ID: 38714203
[TBL] [Abstract][Full Text] [Related]
11. Current advances in the treatment of systemic sclerosis.
Bukiri H; Volkmann ER
Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the management of systemic sclerosis-associated interstitial lung disease.
Hoffmann-Vold AM; Distler O; Crestani B; Antoniou KM
Curr Opin Pulm Med; 2022 Sep; 28(5):441-447. PubMed ID: 35855572
[TBL] [Abstract][Full Text] [Related]
13. Treatment for systemic sclerosis-associated interstitial lung disease.
Roofeh D; Lescoat A; Khanna D
Curr Opin Rheumatol; 2021 May; 33(3):240-248. PubMed ID: 33741803
[TBL] [Abstract][Full Text] [Related]
14. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
[TBL] [Abstract][Full Text] [Related]
16. Should we use nintedanib as early therapy in patients with SSc-ILD?
Zanatta E; Moccaldi B; Szucs G; Spagnolo P
Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
18. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
[TBL] [Abstract][Full Text] [Related]
19. Systemic sclerosis-associated interstitial lung disease.
Scallan CJ; Collins BF; Raghu G
Curr Opin Pulm Med; 2020 Sep; 26(5):487-495. PubMed ID: 32740379
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
Mendoza FA; Allawh T; Jimenez SA
Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
